Scientists uncover mechanism behind drug resistance in bowel cancer
Scientists at The Institute of Cancer Research (ICR), London, have discovered what may cause some treatments to stop working in people living with bowel cancer.
The findings could help researchers use information about a person’s cancer to make better use of current treatments and develop more targeted therapies for bowel cancer.
In research published in Cancer Research, the team studied two sets of bowel cancer organoids with different genetic makeups and how they responded to four cancer treatments given in different sequences over 45-day periods.
The study found that cancer cells can develop a ‘memory, through the switching on and off of certain processes in the cell, or ‘epigenetic changes’. Cells can ‘remember’ the form and appearance they need to adopt to survive harsh conditions, like being bombarded by cancer drugs.
The resulting survival mode ‘memories’ are then passed on when cancer cells grow and divide, resulting in a cluster of drug-resistant cancer cells.
Senior Scientific Officer at the ICR and one of the lead authors of the paper, Dr Erica Oliveira, said: “We have known for some time now that drug resistance isn’t simply caused by further mutations in the DNA of cancer cells. Our work shows the additional role epigenetic changes play in giving cancer cells the ability to adapt to their surroundings, unfortunately resulting in certain cancer treatments becoming less effective over time.
“We look forward to further studying these processes to see if we can target them directly as a strategy for beating bowel cancer.”
The work was funded by Cancer Research UK and the Italian Association for Cancer Research (AIRC) with additional support from the Wellcome Trust, the National Institute for Health Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (ICR), and Imperial College London.
Diana Spencer, Senior Digital Content Editor, DDW
